A Review of the Literature on Osteonecrosis of the Jaw in Patients with Osteoporosis Treated with Oral Bisphosphonates: Prevalence, Risk Factors, and Clinical Characteristics

Lane, 2006, Epidemiology, etiology, and diagnosis of osteoporosis, Am J Obstet Gynecol, 194, S3, 10.1016/j.ajog.2005.08.047 2004, Bone health and osteoporosis: A report of the Surgeon General Miller, 1999, Management of osteoporosis, Dis Mon, 45, 21, 10.1016/S0011-5029(99)90010-X Tosteson, 2001, Impact of hip and vertebral fractures on quality-adjusted life years, Osteoporos Int, 12, 1042, 10.1007/s001980170015 Stafford, 2004, National trends in osteoporosis visits and osteoporosis treatment, 1988-2003, Arch Intern Med, 164, 1525, 10.1001/archinte.164.14.1525 2007, Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws, J Oral Maxillofac Surf, 65, 369, 10.1016/j.joms.2006.11.003 Cummings, 1998, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture Intervention TriaI, JAMA, 280, 2077, 10.1001/jama.280.24.2077 Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2 Delmas, 2004, Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study, Osteoporos Int, 15, 792, 10.1007/s00198-004-1602-9 Harris, 1999, Effects ofrisedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial, JAMA, 282, 1344, 10.1001/jama.282.14.1344 Delmas, 2006, Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study, Arthritis Rheum, 54, 1838, 10.1002/art.21918 Roelofs, 2006, Molecular mechanisms of action of bisphosphonates: Current status, Clin Cancer Res, 12, 62225, 10.1158/1078-0432.CCR-06-0843 Ott, 2005, Long-term safety of bisphosphonates, J Clin Endocrinol Metab, 90, 1897, 10.1210/jc.2005-0057 Greenspan, 2000, Bisphosphonates: Safety and efficacy in the treatment and prevention of osteoporosis, Am Faro Physician, 61, 2731 Iwamoto, 2006, Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis, Curr Med Res Opin, 22, 919, 10.1185/030079906X100276 Marx, 2003, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic, J Oral Maxillofac Surg, 61, 1115, 10.1016/S0278-2391(03)00720-1 Bilezikian, 2006, Osteonecrosis of the jaw-do bisphosphonates pose a risk?, N Engl J Med, 355, 2278, 10.1056/NEJMp068157 Shane, 2006, Osteonecrosis of the jaw: More research needed, J Bone Miner Res, 21, 1503, 10.1359/jbmr.060712 Van den Wyngaert, 2006, Bisphosphonates and osteonecrosis of the jaw: Cause and effect or a post hoc fallacy?, Ann Oncol, 17, 1197, 10.1093/annonc/mdl294 Assouline-Dayan, 2002, Pathogenesis and natural history ofosteonecrosis, Semin Arthritis Rheum, 32, 94, 10.1053/sarh.2002.33724b Capsoni, 2006, Bisphosphonate-associated osteonecrosis of the jaw: The rheumatologist's role, Arthritis Res Ther, 8, 219, 10.1186/ar2050 Pamer Woo, 2006, Narrative review: Bisphosphonates and osteonecrosis of the jaws, Ann Intern Med, 144, 753, 10.7326/0003-4819-144-10-200605160-00009 Krueger, 2007, Bisphosphonate-induced osteonecrosis of the jaw, Ann Pharmacother, 41, 276, 10.1345/aph.1H521 Ruggiero, 2004, Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases, J Oral Maxillofac Surg, 62, 527, 10.1016/j.joms.2004.02.004 Nase, 2006, Osteonecrosis of the jaw and oral bisphosphonate treatment, J Am Dent Assoc, 137, 1115, 10.14219/jada.archive.2006.0350 Yeo, 2005, Bisphosphonate-related osteonecrosis of the jaws, Singapore Dent J, 27, 36 Purcell, 2005, Bisphosphonates and osteonecrosis of the jaw, Med J Aust, 182, 417, 10.5694/j.1326-5377.2005.tb06762.x Farrugia, 2006, Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonares, Laryngoscope, 116, 115, 10.1097/01.mlg.0000187398.51857.3c Marunick, 2005, Adverse oral sequelae to bisphosphonate administration, J Mich Dent Assoc, 87, 44 Kademani, 2006, Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy, Mayo Clin Proc, 81, 1100, 10.4065/81.8.1100 RE, 2005, Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment, J Oral Maxillofac Surg, 63, 1567, 10.1016/j.joms.2005.07.010 Migliorati, 2005, Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy, Cancer, 104, 83, 10.1002/cncr.21130 Cheng, 2005, The dental implications of bisphosphonates and bone disease, Aust Dent J, 50, S4, 10.1111/j.1834-7819.2005.tb00384.x Merigo, 2006, Bone necrosis of the jaws associated with bisphosphonate treatment: A report of twenty-nine cases, Acta Biomed, 77, 109 Mavrokokki, 2007, Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia, J Oral Maxillofac Surg, 65, 415, 10.1016/j.joms.2006.10.061 Khosla, 2007, Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research, J Bone Miner Res, 10.1359/jbmr.0707onj Migliorati, 2006, Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment, Lancet Oncol, 7, 508, 10.1016/S1470-2045(06)70726-4 Berenson, 1997, Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function, J Clin Pharmacol., 37, 285, 10.1002/j.1552-4604.1997.tb04304.x Ezra, 2000, Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption, Adv Drug Deliv Rev, 42, 175, 10.1016/S0169-409X(00)00061-2 Black, 2006, Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in post-menopausal women with osteoporosis: The HORIZON Pivotal Fracture Trial, J Bone Miner Res, 21, 1054 Sambrook, 2006, Bisphosphonates and osteonecrosis of the jaw, Aust Faro Physician, 35, 801 American Dental Association Council on Scientific Affairs, 2006, J Am Dent Assoc, 137, 1144, 10.14219/jada.archive.2006.0355 Odvina, 2005, Severely suppressed bone turnover: A potential complication of alendronate therapy, J Clin Endocrinol Metab, 90, 1294, 10.1210/jc.2004-0952 Migliorati, 2005, Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper, J Am Dent Assoc, 136, 1658, 10.14219/jada.archive.2005.0108 Bamias, 2005, Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors, J Clin Oncol, 23, 8580, 10.1200/JCO.2005.02.8670 Kuehn, 2005, Longer-lasting osteoporosis drugs sought, JAMA, 293, 2458, 10.1001/jama.293.20.2458 Badros, 2006, Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors, J Clin Oncol, 24, 945, 10.1200/JCO.2005.04.2465 Wood, 2002, Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid, J Pharmacol Exp Ther, 302, 1055, 10.1124/jpet.102.035295 Fournier, 2002, Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats, Cancer Res, 62, 6538 Santini, 2003, Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients, Clin Cancer Res, 9, 2893